TABLE 2.
Antimicrobial susceptibility profiles of vancomycin-resistant and -susceptible E. faecium isolates from CANWARD study
| Antimicrobial used | Susceptibility profile (%)a |
MIC range (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | ||
|---|---|---|---|---|---|---|
| S | I | R | ||||
| Vancomycin-resistant enterococci | ||||||
| Ciprofloxacin | 100 | >16 | >16 | >16 | ||
| Levofloxacin | 100 | >32 | >32 | >32 | ||
| Vancomycin | 100 | >32 | >32 | >32 | ||
| Doxycycline | 70.6 | 8.8 | 20.6 | ≤0.12 to 16 | 2 | 16 |
| Linezolid | 86.3 | 13.8 | 0.5 to 4 | 2 | 4 | |
| Daptomycin | 100 | ≤0.06 to 2 | 1 | 2 | ||
| Vancomycin-susceptible enterococci | ||||||
| Ciprofloxacin | 44.7 | 12.8 | 42.5 | ≤0.06 to >16 | 2 | >16 |
| Levofloxacin | 58.1 | 0.8 | 41.1 | ≤0.06 to >32 | 2 | >32 |
| Vancomycin | 100 | ≤0.25 to 4 | 1 | 2 | ||
| Doxycycline | 51.6 | 32.7 | 15.7 | ≤0.12 to 32 | 4 | 16 |
| Linezolid | 95.5 | 4.5 | ≤0.12 to 4 | 2 | 2 | |
| Daptomycin | 100 | ≤0.06 to 4 | 0.5 | 2 | ||
a
S, susceptible; I, intermediate; R, resistant.